Identification of Potential Cytokine Pathways for Therapeutic Intervention in Murine Primary Biliary Cirrhosis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Kawata, Kazuhito ^a,b   Tsuda, Masanobu ^a,c   Yang, Guo Xiang ^a   Zhang, Weici ^a   Tanaka, Hajime ^a   Tsuneyama, Koichi ^a,d   Leung, Patrick ^a   He, Xiao Song ^a   Knechtle, Stuart ^e   Ansari, Aftab A ^f   Coppel, Ross L ^g   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

^e EMORY CLINIC   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23P19; MITOCHONDRION ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLANGITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE DELETION; IMMUNOPATHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; CHOLANGITIS; DISEASE MODELS, ANIMAL; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION REGULATION; HUMANS; IMMUNOCONJUGATES; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-17; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS; LIVER; LIVER CIRRHOSIS, BILIARY; MICE; MICE, KNOCKOUT; MITOCHONDRIA; SERUM ALBUMIN, BOVINE; SIGNAL TRANSDUCTION; TH1-TH2 BALANCE;

EID: 84883826611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074225     Document Type: Article

References (40)

1. Harada K, Van de Water J, Leung PS, Coppel RL, Ansari A, et al. (1997) In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 25: 791-796.
2. Shindo M, Mullin GE, Braun-Elwert L, Bergasa NV, Jones EA, et al. (1996) Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB). Clin Exp Immunol 105: 254-259.
3. Lan RY, Salunga TL, Tsuneyama K, Lian ZX, Yang GX, et al. (2009) Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 32: 43-51.
4. Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, et al. (2009) Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 157: 261-270.
5. Rong G, Zhou Y, Xiong Y, Zhou L, Geng H, et al. (2009) Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol 156: 217-225.
6. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, et al. (2006) Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 177: 1655-1660.
7. Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, et al. (2009) Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 50: 1494-1500.
8. Tsuda M, Zhang W, Yang GX, Tsuneyama K, Ando Y, et al. (2013) Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFbeta receptor type II mice. Hepatology 57: 806-816.
9. Ando Y, Yang GX, Tsuda M, Kawata K, Zhang W, et al. (2012) The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology 56: 1418-1426.
10. Wakabayashi K, Lian ZX, Leung PS, Moritoki Y, Tsuneyama K, et al. (2008) Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology 48: 531-540.
11. Dhirapong A, Lleo A, Yang GX, Tsuneyama K, Dunn R, et al. (2011) B cell depletion therapy exacerbates murine primary biliary cirrhosis. Hepatology 53: 527-535.
12. Dhirapong A, Yang GX, Nadler S, Zhang W, Tsuneyama K, et al. (2013) Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 57: 708-715.
13. Ambrosini YM, Yang GX, Zhang W, Tsuda M, Shu S, et al. (2011) The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin Exp Immunol 166: 110-120.
14. Moritoki Y, Zhang W, Tsuneyama K, Yoshida K, Wakabayashi K, et al. (2009) B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 136: 1037-1047.
15. van Wanrooij RL, Zwiers A, Kraal G, Bouma G, (2012) Genetic variations in interleukin-12 related genes in immune-mediated diseases. J Autoimmun 39: 359-368.
16. Brand S, (2009) Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58: 1152-1167.
17. Dardalhon V, Korn T, Kuchroo VK, Anderson AC, (2008) Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 31: 252-256.
18. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, et al. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
19. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.
20. Luger D, Silver PB, Tang J, Cua D, Chen Z, et al. (2008) Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 205: 799-810.
21. Zhang J, Huang Z, Sun R, Tian Z, Wei H, (2012) IFN-gamma induced by IL-12 administration prevents diabetes by inhibiting pathogenic IL-17 production in NOD mice. J Autoimmun 38: 20-28.
22. Trinchieri G, Pflanz S, Kastelein RA, (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19: 641-644.
23. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, et al. (2004) IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 202: 96-105.
24. Hunter CA, (2005) New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5: 521-531.
25. Li L, Huang L, Vergis AL, Ye H, Bajwa A, et al. (2010) IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest 120: 331-342.
26. Wozniak TM, Ryan AA, Triccas JA, Britton WJ, (2006) Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun 74: 557-565.
27. Lee S, French MA, Price P, (2004) IL-23 and IFN-gamma deficiency in immunodeficient HIV patients who achieved a long-term increase in CD4 T-cell counts on highly active antiretroviral therapy. AIDS 18: 1337-1340.
28. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, et al. (2006) Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. The Journal of clinical investigation 116: 1317-1326.
29. Haylock-Jacobs S, Comerford I, Bunting M, Kara E, Townley S, et al. (2011) PI3Kdelta drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J Autoimmun 36: 278-287.
30. Singh N, Cohen PL, (2012) The T cell in Sjogren's syndrome: force majeure, not spectateur. J Autoimmun 39: 229-233.
31. Chen DY, Chen YM, Wen MC, Hsieh TY, Hung WT, et al. (2012) The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 21: 1385-1396.
32. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, et al. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
33. Becher B, Durell BG, Noelle RJ, (2002) Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 110: 493-497.
34. Gran B, Zhang GX, Yu S, Li J, Chen XH, et al. (2002) IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 169: 7104-7110.
35. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, et al. (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177: 566-573.
36. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, et al. (1996) Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156: 5-7.
37. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA, (1996) IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 157: 3223-3227.
38. Gorelik L, Flavell RA, (2000) Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12: 171-181.
39. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, et al. (2009) Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis and rheumatism 60: 390-395.
40. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, et al. (2008) IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. The Journal of clinical investigation 118: 534-544.